BfArM — authorised 25 April 2022
- Marketing authorisation holder: BIOHAVEN PHARMACEUTICAL IRELAND DAC
- Status: approved
BfArM authorised Nurtec Odt on 25 April 2022
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. BfArM authorised it on 25 April 2022.
BIOHAVEN PHARMACEUTICAL IRELAND DAC holds the German marketing authorisation.